Results 191 to 200 of about 42,609 (234)

Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief

Expert Review of Respiratory Medicine, 2020
Objectives: This study aimed to assess the efficacy of oseltamivir-Azithromycin combination therapy for prevention of Influenza-A (H1N1)pdm09 infection associated complications and early relief of influenza symptoms.
A. Ishaqui, A. Khan, S. Sulaiman, M. Alsultan, Irfanullah Khan, A. Naqvi   +5 more
semanticscholar   +1 more source

Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: a French multicenter observational cohort study.

Clinical Infectious Diseases, 2020
In a multicenter cohort study including 22 oseltamivir-treated patients with influenza A(H1N1)pdm09 acute respiratory distress syndrome, prevalence of the H275Y substitution in the neuraminidase, responsible for highly reduced sensitivity to oseltamivir,
S. Behillil, Faten May, S. Fourati, C. Luyt, T. Chicheportiche, R. Sonneville, Yacine Tandjaoui-Lambiotte, D. Roux, L. Guérin, J. Mayaux, É. Maury, A. Ferré, Jean-François Georger, G. Voiriot, V. Enouf, S. van der Werf, A. Dessap, N. de Prost   +17 more
semanticscholar   +1 more source

Oseltamivir and the risk of neuropsychiatric events: a national, population-based study.

Clinical Infectious Diseases, 2020
BACKGROUND Reports of serious neuropsychiatric events (NPEs), specifically suicide/suicide attempts following the use of oseltamivir, have led to public concerns.
K. Huh, Minsun Kang, D. Shin, Jinwook Hong, Jaehun Jung   +4 more
semanticscholar   +1 more source

Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling

AAPS PharmSciTech, 2020
Oseltamivir is a neuraminidase inhibitor widely used to treat and prevent influenza A and B infections, although its safety and pharmacokinetics have not been evaluated in patients with severe hepatic impairment.
Yong Chen, Meng Ke, Jianwen Xu, Cuihong Lin   +3 more
semanticscholar   +1 more source

Baloxavir treatment of oseltamivir‐resistant influenza A/H1pdm09 in two immunocompromised patients

Transplant Infectious Disease, 2020
Few treatment options are available for oseltamivir‐resistant influenza. It has been proposed that baloxavir can be effective in this setting due to its distinct mechanism of action but clinical experience is lacking for immunocompromised patients.
N. Macesic, Jennifer Laplante, J. Aaron, E. DiMango, Benjamin A. Miko, Marcus R. Pereira, R. Reshef, K. St. George   +7 more
semanticscholar   +1 more source

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials

Lancet, The, 2015
Stuart J Pocock, Arnold S Monto
exaly   +2 more sources

Oseltamivir

Reactions Weekly, 2010
  +8 more sources

Oseltamivir

Reactions Weekly, 2015
  +8 more sources

Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multi-season cohort study.

Clinical Infectious Diseases, 2019
Background The available evidence on whether neuraminidase inhibitors reduce mortality in patients with influenza is inconclusive, and focuses solely on influenza A/H1N1pdm09. We assessed whether early oseltamivir treatment (≤48 hours from symptom onset)
T. Lytras, E. Mouratidou, Anastasia Andreopoulou, S. Bonovas, S. Tsiodras   +4 more
semanticscholar   +1 more source

A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.

Veterinary Microbiology, 2019
Occurrence of avian influenza (AI) with Neuraminidase (NA) mutations which confer reduced neuraminidase inhibitor (NAI) susceptibility has remained a cause of concern.
Sadhana S. Kode, S. Pawar, Deeksha S. Tare, Sachin S Keng, A. Hurt, J. Mullick   +5 more
semanticscholar   +1 more source